|
1
|
Bai J, Li D, Yang P, Xu K, Wang Y, Li Q,
Liu J, Du W, Zhang F and Feng R: Camrelizumab-Related myocarditis
and myositis with myasthenia gravis: A case report and literature
review. Front Oncol. 11(778185)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yin B, Xiao J, Li J, Liu X and Wang J:
Immune-related organizing pneumonitis in non-small cell lung cancer
receiving PD-1 inhibitor treatment: A case report and literature
review. J Cancer Res Ther. 16:1555–1559. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Weinmann SC and Pisetsky DS: Mechanisms of
immune-related adverse events during the treatment of cancer with
immune checkpoint inhibitors. Rheumatology (Oxford). 58 (Suppl
7):vii59–vii67. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Huang Y, Liang D, Liu J, Zeng J and Zeng
Y: The breakthroughs in cancer immune checkpoint based therapy: A
review of development in immune checkpoint study and its
application. Comb Chem High Throughput Screen. 20:430–439.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yang H, Zhou C, Yuan F, Guo L, Yang L, Shi
Y and Zhang J: Case report: Severe immune-related cholestatic
hepatitis and subsequent pneumonia after pembrolizumab therapy in a
geriatic patient with metastic gastric cancer. Front Med
(Lausanne). 8(719236)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Naidoo J, Page DB, Li BT, Connell LC,
Schindler K, Lacouture ME, Postow MA and Wolchok JD: Toxicities of
the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann
Oncol. 26:2375–2391. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Safa H, Bhosale P, Weissferdt A and Oliva
ICG: Difficulties in differentiating between checkpoint inhibitor
pneumonitis and lung metastasis in a patient with melanoma.
Immunotherapy. 12:293–298. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Couey MA, Bell RB, Patel AA, Romba MC,
Crittenden MR, Curti BD, Urba WJ and Leidner RS: Delayed
immune-related events (DIRE) after discontinuation of
immunotherapy: Diagnostic hazard of autoimmunity at a distance. J
Immunother Cancer. 7(165)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Takeno A, Yamamoto M, Morita M, Tanaka S,
Kanazawa I, Yamauchi M, Kaneko S and Sugimoto T: Late-onset
isolated adrenocorticotropic hormone deficiency caused by
nivolumab: A case report. BMC Endocr Disord. 19(25)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Antoniou S, Bazazo G, Rockl L, Papadakis M
and Berg C: Late-onset hypophysitis after discontinuation of
nivolumab treatment for advanced skin melanoma: A case report. BMC
Endocr Disord. 21(191)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mae S, Kuriyama A and Tachibana H:
Diabetic ketoacidosis as a delayed immune-related event after
discontinuation of nivolumab. J Emerg Med. 60:342–344.
2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yaura K, Sakurai K, Niitsuma S, Sato R,
Takahashi K and Arihara Z: Fulminant type 1 diabetes mellitus
developed about half a year after discontinuation of immune
checkpoint inhibitor combination therapy with nivolumab and
ipilimumab: A case report. Tohoku J Exp Med. 254:253–256.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kanaoka K, Moriizumi K, Okada H, Iwahashi
K, Tsuji H, Yasuoka H and Minami S: Pembrolizumab-Induced
delayed-onset hepatitis. Case Rep Gastroenterol. 14:586–592.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fu S, Wang T and Xu F: Delayed immune
thrombocytopenia after discontinuation of nivolumab therapy: A case
report and literature review. J Oncol Pharm Pract. 27:1548–1552.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kucukarda A, Gokmen I, Ozcan E, Peker P,
Akgul F and Cicin I: Recurrent delayed immune-related pneumonitis
after immune-checkpoint inhibitor therapy for advanced
osteosarcoma. Immunotherapy. 14:395–399. 2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–1728.
2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Friedman CF, Proverbs-Singh TA and Postow
MA: Treatment of the immune-related adverse effects of immune
checkpoint inhibitors: A review. JAMA Oncol. 2:1346–1353.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Naidoo J, Wang X, Woo KM, Iyriboz T,
Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin
AM, et al: Pneumonitis in patients treated with anti-programmed
death-1/programmed death ligand 1 therapy. J Clin Oncol.
35:709–717. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Diamantopoulos PT, Gaggadi M, Kassi E,
Benopoulou O, Anastasopoulou A and Gogas H: Late-onset
nivolumab-mediated pneumonitis in a patient with melanoma and
multiple immune-related adverse events. Melanoma Res. 27:391–395.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kimura H, Sone T, Araya T, Murata A,
Yamamura K, Ohkura N, Hara J, Abo M and Kasahara K: Late-onset
programmed cell death protein-1 inhibitor-induced pneumonitis after
cessation of nivolumab or pembrolizumab in patients with advanced
non-small cell lung cancer: A case series. Transl Lung Cancer Res.
10:1576–1581. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nakai Y, Otsuka T, Inoue T, Nawa T, Hatano
K, Yamamoto Y, Nagahara A, Nakayama M, Kakimoto KI and Nishimura K:
Two cases of delayed onset of immune-related adverse events after
discontinuation of nivolumab in patients with metastatic renal cell
cancer. IJU Case Rep. 4:326–329. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mandala M, Merelli B, Indriolo A and
Tondini C: Late-occurring toxicity induced by an immune checkpoint
blockade in adjuvant treatment of a stage III melanoma patient. Eur
J Cancer. 95:130–132. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yi Y, Liu Z, Fang L, Li J, Liu W, Wang F,
Fu P, Xie C, Liu J and Song B: Comparison between single-agent and
combination chemotherapy as second-line treatment for advanced
non-small cell lung cancer: A multi-institutional retrospective
analysis. Cancer Chemother Pharmacol. 86:65–74. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Brahmer JR, Lacchetti C, Schneider BJ,
Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner
JM, Ginex P, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: American
Society of clinical oncology clinical practice guideline. J Clin
Oncol. 36:1714–1768. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Naranjo CA, Busto U, Sellers EM, Sandor P,
Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ: A method
for estimating the probability of adverse drug reactions. Clin
Pharmacol Ther. 30:239–245. 1981.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Johnson DB, Nebhan CA, Moslehi JJ and
Balko JM: Immune-checkpoint inhibitors: Long-term implications of
toxicity. Nat Rev Clin Oncol. 19:254–267. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Qu Y, Wang Z, Feng J, Wang L, Liu H, Liu
D, Zhao Y, Yu R, Li W, Sun D and Yu H: Pneumonitis, appendicitis,
and biliary obstruction during toripalimab treatment in a patient
with extensive-stage small-cell lung cancer: A case report. Ann
Palliat Med. 10:9267–9275. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Khunger M, Rakshit S, Pasupuleti V,
Hernandez AV, Mazzone P, Stevenson J, Pennell NA and Velcheti V:
Incidence of pneumonitis with use of programmed death 1 and
programmed death-ligand 1 inhibitors in non-small cell lung cancer:
A systematic review and meta-analysis of trials. Chest.
152:271–281. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sullivan RJ, Johnson DB, Rini BI, Neilan
TG, Lovly CM, Moslehi JJ and Reynolds KL: COVID-19 and immune
checkpoint inhibitors: Initial considerations. J Immunother Cancer.
8(e000933)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li L, Lou A and Yu J: Immune checkpoint
inhibitor-related pneumonitis induced by camrelizumab: A case
report and review of literature. Ann Palliat Med. 10:8460–8466.
2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang H, Guo X, Zhou J, Li Y, Duan L, Si X
and Zhang L, Liu X, Wang M, Shi J and Zhang L: Clinical diagnosis
and treatment of immune checkpoint inhibitor-associated
pneumonitis. Thorac Cancer. 11:191–197. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Skeoch S, Weatherley N, Swift AJ, Oldroyd
A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, et
al: Drug-Induced interstitial lung disease: A systematic review. J
Clin Med. 7(356)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Spagnolo P, Bonniaud P, Rossi G,
Sverzellati N and Cottin V: Drug-induced interstitial lung disease.
Eur Respir J. 60(2102776)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Min BD, Kang HW, Kim WT, Kim YJ, Yun SJ,
Lee SC and Kim WJ: Docetaxel-induced fatal interstitial pneumonitis
in a patient with castration-resistant prostate cancer. Korean J
Urol. 53:371–374. 2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang CJ, Chang HT and Chang CY:
Docetaxel-related interstitial pneumonitis. Ther Clin Risk Manag.
11:1813–1816. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hoy SM: Sintilimab: First global approval.
Drugs. 79:341–346. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Shi Y, Su H, Song Y, Jiang W, Sun X, Qian
W, Zhang W, Gao Y, Jin Z, Zhou J, et al: Safety and activity of
sintilimab in patients with relapsed or refractory classical
Hodgkin lymphoma (ORIENT-1): A multicentre, single-arm, phase 2
trial. Lancet Haematol. 6:e12–e19. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shibata Y, Murakami S and Kato T: Overview
of checkpoint inhibitor pneumonitis: Incidence and associated risk
factors. Expert Opin Drug Saf. 20:537–547. 2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Leroy V, Templier C, Faivre JB,
Scherpereel A, Fournier C, Mortier L and Wemeau-Stervinou L:
Pembrolizumab-induced pneumonitis. ERJ Open Res. 3:00081–2016.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Delaunay M, Cadranel J, Lusque A, Meyer N,
Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N,
Guisier F, et al: Immune-checkpoint inhibitors associated with
interstitial lung disease in cancer patients. Eur Respir J.
50(1700050)2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Pozzessere C, Bouchaab H, Jumeau R,
Letovanec I, Daccord C, Bourhis J, Prior JO, Peters S, Lazor R and
Beigelman-Aubry C: Relationship between pneumonitis induced by
immune checkpoint inhibitors and the underlying parenchymal status:
A retrospective study. ERJ Open Res. 6:00165–2019. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Danlos FX, Voisin AL, Dyevre V, Michot JM,
Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges
L, et al: Safety and efficacy of anti-programmed death 1 antibodies
in patients with cancer and pre-existing autoimmune or inflammatory
disease. Eur J Cancer. 91:21–29. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Cortellini A, Buti S, Santini D, Perrone
F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A,
Brocco D, et al: Clinical outcomes of patients with advanced cancer
and pre-existing autoimmune diseases treated with anti-programmed
death-1 immunotherapy: A real-world transverse study. Oncologist.
24:e327–e337. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Griffiths CE and Barker JN: Pathogenesis
and clinical features of psoriasis. Lancet. 370:263–271.
2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Halle BR, Betof Warner A, Zaman FY, Haydon
A, Bhave P, Dewan AK, Ye F, Irlmeier R, Mehta P, Kurtansky NR, et
al: Immune checkpoint inhibitors in patients with pre-existing
psoriasis: Safety and efficacy. J Immunother Cancer.
9(e003066)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kimura H, Sone T, Murata A, Koba H, Tambo
Y, Hara J, Abo M and Kasahara K: Long-lasting shrinkage in tumour
mass after discontinuation of nivolumab treatment. Lung Cancer.
108:7–8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Pesola G, Murianni V, Rebuzzi SE, Banna
GL, Cerbone L, Catalano F, Borea R, Gandini A, Cremante M, Puglisi
S, et al: Durable response after immunotherapy discontinuation for
delayed and severe immune-related adverse events: A case report.
Immunotherapy. 13:1379–1386. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Umihira S, Koyanagi T, Tamura K, Takahashi
Y, Yoshiba T, Takahashi S, Taneichi A, Saga Y, Takei Y and Fujiwara
H: Durable response after the discontinuation of pembrolizumab
treatment due to an adverse event in a patient with advanced
endometrial cancer: A case report. Exp Ther Med.
23(409)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Eguchi S, Shinkawa H, Sato Y, Nakai K,
Takemura S, Tanaka S, Amano R, Kimura K, Ohira G, Nishio K, et al:
Durable response after discontinuation of pembrolizumab therapy for
intrahepatic cholangiocarcinoma: A case report. Clin J
Gastroenterol. 14:858–865. 2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Brahmer JR, Drake CG, Wollner I, Powderly
JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller
TL, et al: Phase I study of single-agent anti-programmed death-1
(MDX-1106) in refractory solid tumours: Safety, clinical activity,
pharmacodynamics, and immunologic correlates. J Clin Oncol.
28:3167–3175. 2010.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhang L, Lin W, Tan F, Li N, Xue Q, Gao S,
Gao Y and He J: Sintilimab for the treatment of non-small cell lung
cancer. Biomark Res. 10(23)2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S,
Ni H, Chen B, Xiong Y, Liu Y, et al: Durable blockade of PD-1
signaling links preclinical efficacy of sintilimab to its clinical
benefit. MAbs. 11:1443–1451. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Haanen JBAG, Carbonnel F, Robert C, Kerr
KM, Peters S, Larkin J and Jordan K: ESMO Guidelines Committee.
Management of toxicities from immunotherapy: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28
(suppl_4):iv119–iv142. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Phan T, Patwala K, Lipton L, Knight V, Aga
A and Pianko S: Very delayed acute hepatitis after pembrolizumab
therapy for advanced malignancy: How long should we watch? Curr
Oncol. 28:898–902. 2021.PubMed/NCBI View Article : Google Scholar
|
